Cargando…
Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9894356/ https://www.ncbi.nlm.nih.gov/pubmed/36751513 http://dx.doi.org/10.1097/HS9.0000000000000829 |
| _version_ | 1784881724297052160 |
|---|---|
| author | Ocio, Enrique M. Bringhen, Sara Martinez-Lopez, Joaquin San-Miguel, Jesus Oliva, Stefania Rodriguez-Otero, Paula Le Roux, Nadia Dong, Yvonne Doroumian, Severine Macé, Sandrine Mateos, Maria-Victoria |
| author_facet | Ocio, Enrique M. Bringhen, Sara Martinez-Lopez, Joaquin San-Miguel, Jesus Oliva, Stefania Rodriguez-Otero, Paula Le Roux, Nadia Dong, Yvonne Doroumian, Severine Macé, Sandrine Mateos, Maria-Victoria |
| author_sort | Ocio, Enrique M. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9894356 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-98943562023-02-06 Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients Ocio, Enrique M. Bringhen, Sara Martinez-Lopez, Joaquin San-Miguel, Jesus Oliva, Stefania Rodriguez-Otero, Paula Le Roux, Nadia Dong, Yvonne Doroumian, Severine Macé, Sandrine Mateos, Maria-Victoria Hemasphere Letter Lippincott Williams & Wilkins 2023-01-31 /pmc/articles/PMC9894356/ /pubmed/36751513 http://dx.doi.org/10.1097/HS9.0000000000000829 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License (https://creativecommons.org/licenses/by-nc-sa/4.0/) , which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. |
| spellingShingle | Letter Ocio, Enrique M. Bringhen, Sara Martinez-Lopez, Joaquin San-Miguel, Jesus Oliva, Stefania Rodriguez-Otero, Paula Le Roux, Nadia Dong, Yvonne Doroumian, Severine Macé, Sandrine Mateos, Maria-Victoria Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients |
| title | Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients |
| title_full | Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients |
| title_fullStr | Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients |
| title_full_unstemmed | Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients |
| title_short | Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients |
| title_sort | phase 1b study of isatuximab in combination with bortezomib, cyclophosphamide, and dexamethasone in newly diagnosed, transplant-ineligible multiple myeloma patients |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9894356/ https://www.ncbi.nlm.nih.gov/pubmed/36751513 http://dx.doi.org/10.1097/HS9.0000000000000829 |
| work_keys_str_mv | AT ocioenriquem phase1bstudyofisatuximabincombinationwithbortezomibcyclophosphamideanddexamethasoneinnewlydiagnosedtransplantineligiblemultiplemyelomapatients AT bringhensara phase1bstudyofisatuximabincombinationwithbortezomibcyclophosphamideanddexamethasoneinnewlydiagnosedtransplantineligiblemultiplemyelomapatients AT martinezlopezjoaquin phase1bstudyofisatuximabincombinationwithbortezomibcyclophosphamideanddexamethasoneinnewlydiagnosedtransplantineligiblemultiplemyelomapatients AT sanmigueljesus phase1bstudyofisatuximabincombinationwithbortezomibcyclophosphamideanddexamethasoneinnewlydiagnosedtransplantineligiblemultiplemyelomapatients AT olivastefania phase1bstudyofisatuximabincombinationwithbortezomibcyclophosphamideanddexamethasoneinnewlydiagnosedtransplantineligiblemultiplemyelomapatients AT rodriguezoteropaula phase1bstudyofisatuximabincombinationwithbortezomibcyclophosphamideanddexamethasoneinnewlydiagnosedtransplantineligiblemultiplemyelomapatients AT lerouxnadia phase1bstudyofisatuximabincombinationwithbortezomibcyclophosphamideanddexamethasoneinnewlydiagnosedtransplantineligiblemultiplemyelomapatients AT dongyvonne phase1bstudyofisatuximabincombinationwithbortezomibcyclophosphamideanddexamethasoneinnewlydiagnosedtransplantineligiblemultiplemyelomapatients AT doroumianseverine phase1bstudyofisatuximabincombinationwithbortezomibcyclophosphamideanddexamethasoneinnewlydiagnosedtransplantineligiblemultiplemyelomapatients AT macesandrine phase1bstudyofisatuximabincombinationwithbortezomibcyclophosphamideanddexamethasoneinnewlydiagnosedtransplantineligiblemultiplemyelomapatients AT mateosmariavictoria phase1bstudyofisatuximabincombinationwithbortezomibcyclophosphamideanddexamethasoneinnewlydiagnosedtransplantineligiblemultiplemyelomapatients |